20Indexed trials
drug · Product Intelligence
Atomoxetine
Pipeline Intelligence
Atomoxetine: 20 indexed trials, 17 sponsors; 0 linked Orange Book patents and 4 FDA-linked events where matched.
17Sponsors
0Orange Book patent links
4FDA-linked events
Development evidence
NCT00191880Eli Lilly and Company · adhdPHASE3
NCT00286949Johns Hopkins University · parkinsonsNA
NCT00360269Medical University of South Carolina · adhdPHASE2
NCT00418262University of Oklahoma · adhdPHASE3
NCT00429091Abbott · adhdPHASE2
NCT00447278Eli Lilly and Company · adhdPHASE3
NCT00562055Pfizer · adhdPHASE2
NCT00760747Eli Lilly and Company · adhdPHASE4
NCT00844753University of Rochester · autismPHASE4
NCT00918567State University of New York at Buffalo · adhdPHASE4
NCT01057329Medical University of Vienna · adhdCOMPLETED
NCT01127646Eli Lilly and Company · adhdPHASE4
NCT01339286Peking University · adhdPHASE4
NCT01522404Emory University · alzheimersPHASE2
NCT03661788RWTH Aachen University · adhdPHASE4
FDA / patent evidence
Orange Book match found; no listed patent relation was retained for this product match.
Regulatory context
FDA_APPROVALATOMOXETINE HYDROCHLORIDE · 2018-02-23
FDA_APPROVALATOMOXETINE HYDROCHLORIDE · 2017-05-30
FDA_APPROVALATOMOXETINE HYDROCHLORIDE · 2017-05-30
FDA_APPROVALATOMOXETINE HYDROCHLORIDE · 2010-09-16
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.